Dr. Chung currently serves as chair of the ACR’s Vasculitis Guidelines Development Committee, which is currently looking at the TAKT study and other studies to develop recommendations for the treatment and management of TAK. “We hope these guidelines will help rheumatologists identify the most appropriate treatments for their patients with TAK,” she says.
Carina Stanton is a freelance science writer in Denver.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018 Mar;77(3):348–354.
- Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008 Apr;58(4):1197–1200.
- Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory takayasu arteritis. Int Heart J. 2013;54:405–411.
- Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985 Mar;64(2):89–99.
- Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with takayasu arteritis observed from cross-country research in Japan: Age and sex specificity. Circulation. 2015 Nov 3;132(18):1701–1709.
- JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J. 2011;75(2):474–503.
Additional Resources
Review the ACR’s clinical practice guideline for vasculitis.
Read an abstract discussing preliminary data regarding the long-term open label extension of the TAKT study presented at the 2017 ACR/AHRP Annual Meeting.
